Sign in

NCT06695676Not yet recruiting

Effects of Lurasidone on Left Ventricle Systolic Functions

Evaluation of Left Ventricle Systolic Functions of Patients On Lurasidone

Source: ClinicalTrials.gov · Last updated 19 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

The goal of our study to learn if lurasidone molecule which is used on patients with schizophrenia or bipolar disorder has any cardiotoxic effect.

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
62 (estimated)
First submitted
17 Nov 2024
Start date
Nov 2024
Primary completion date
1 May 2025
Lead sponsor
Aydin Adnan Menderes University
NCT number
NCT06695676

What you commit to

  • Study type: Observational
  • Planned participants: 62
  • From Nov 2024 to the primary completion date, 1 May 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Patients who do not agree to participate to the trial
  • Patient who do not meet the inclusion criteria

Who the study is looking for

  • Aged 18 to 65 years
  • Diagnosed with schizophrenia or bipolar disorder by the psychiatry clinic of our center and indicated to use lurasidone molecule
  • Hasn't been diagnosed with coronary artery disease, any kind of heart failure or severe valvular disease

Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Adnan Menderes University
Coordinator of this site? Confirm its status
AydinTurkey (Türkiye)Unknown status

This page is information, not medical advice. Discuss any trial with your doctor.